Patent intelligence · US
US 9359290
Treatment of cataplexy
Treatment of cataplexy
Patent details — US 9359290
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 7, 2016
- Expiration
- Jun 2, 2036
- Claims
- 22
- CPC classes
- A61K, A61K31/27, A61K31/325, A61K45/06
Quick answer
US 9359290 (Treatment of cataplexy) is held by Jazz Pharmaceuticals International III Limited. Status: granted. Granted Jun 7, 2016. Expires Jun 2, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K31/27, A61K31/325, A61K45/06, A61K9/0053, A61K9/20
More from Jazz Pharmaceuticals International III Limited
Related pharmaceutical patents in our USPTO index.
-
US 12427160
Use of cannabinoids in the treatment of epilepsy
granted -
US 12403136
Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof
granted -
US 12396963
Cannabidiol-type cannabinoid compound
granted -
US 12383512
Cannabidiol-type cannabinoid compound
granted -
US 12383567
Use of cannabinoids in the treatment of epilepsy
granted -
US 12364670
Cannabidiol-type cannabinoid compound
granted -
US 12357586
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
granted -
US 12350253
Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
granted
Frequently asked questions
What is US patent 9359290?
US 9359290 (Treatment of cataplexy) is held by Jazz Pharmaceuticals International III Limited. Status: granted. Granted Jun 7, 2016. Expires Jun 2, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9359290?
Jazz Pharmaceuticals International III Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 89 pharmaceutical patents for this assignee.
When does US 9359290 expire?
Our index shows an expiration date of Jun 2, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.